Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease

Autor: Liana S. Rosenthal, Hyunkeun Ryan Cho, Keith A. Hawkins, Michele K. York, Parkinson's Progression Markers Initiative, Tanya Simuni, Irene H. Richard, Dag Aarsland, Jamie L. Eberling, Daniel Weintraub, Alberto J. Espay, Roy N. Alcalay, Andrew Siderowf, James B. Leverenz, Jamie L. Hamilton, Irene Litvan, Lana M. Chahine, Christopher S. Coffey, Chelsea Caspell-Garcia, Matthew J. Barrett
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
Pediatrics
medicine.medical_treatment
Disease
Behavioral Symptoms
Neurodegenerative
Hypnotic
0302 clinical medicine
Prevalence
80 and over
Longitudinal Studies
Research Articles
Aged
80 and over
Parkinson's Disease
Depression
General Neuroscience
Cognition
Parkinson Disease
Middle Aged
Mental Health
Neurological
Disease Progression
Antidepressant
Female
Research Article
RC321-571
Adult
medicine.medical_specialty
medicine.drug_class
Clinical Sciences
Neurosciences. Biological psychiatry. Neuropsychiatry
Anxiolytic
03 medical and health sciences
Clinical Research
medicine
Anticholinergic
Acquired Cognitive Impairment
Humans
Parkinson’s Progression Markers Initiative
Cognitive Dysfunction
Antipsychotic
RC346-429
Aged
business.industry
Neurosciences
Brain Disorders
030104 developmental biology
Observational study
Neurology (clinical)
Neurology. Diseases of the nervous system
business
030217 neurology & neurosurgery
Zdroj: Annals of Clinical and Translational Neurology, Vol 7, Iss 4, Pp 449-461 (2020)
Annals of clinical and translational neurology, vol 7, iss 4
Annals of Clinical and Translational Neurology
ISSN: 2328-9503
Popis: Author(s): Weintraub, Daniel; Caspell-Garcia, Chelsea; Simuni, Tanya; Cho, Hyunkeun R; Coffey, Christopher S; Aarsland, Dag; Alcalay, Roy N; Barrett, Matthew J; Chahine, Lana M; Eberling, Jamie; Espay, Alberto J; Hamilton, Jamie; Hawkins, Keith A; Leverenz, James; Litvan, Irene; Richard, Irene; Rosenthal, Liana S; Siderowf, Andrew; York, Michele; Parkinson’s Progression Markers Initiative | Abstract: ObjectiveTo determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from disease onset.MethodsProspectively collected, longitudinal (untreated, disease onset to year 5), observational data from Parkinson's Progression Markers Initiative annual visits was used to evaluate prevalence, correlates, and treatment of 10 neuropsychiatric symptoms and cognitive impairment in Parkinson disease participants and matched healthy controls.ResultsOf 423 Parkinson disease participants evaluated at baseline, 315 (74.5%) were assessed at year 5. Eight neuropsychiatric symptoms studied increased in absolute prevalence by 6.2-20.9% at year 5 relative to baseline, and cognitive impairment increased by 2.7-6.2%. In comparison, the frequency of neuropsychiatric symptoms in healthy controls remained stable or declined over time. Antidepressant and anxiolytic/hypnotic use in Parkinson disease were common at baseline and increased over time (18% to 27% for the former; 13% to 24% for the latter); antipsychotic and cognitive-enhancing medication use was uncommon throughout (2% and 5% of patients at year 5); and potentially harmful anticholinergic medication use was common and increased over time. At year 5 the cross-sectional prevalence for having three or more neuropsychiatric disorders/cognitive impairment was 56% for Parkinson disease participants versus 13% for healthy controls, and by then seven of the examined disorders had either occurred or been treated at some time point in the majority of Parkinson disease patients. Principal component analysis suggested an affective disorder subtype only.InterpretationNeuropsychiatric features in Parkinson disease are common from the onset, increase over time, are frequently comorbid, and fluctuate in severity.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje